Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Raxibacumab is a human IgG1λ monoclonal antibody that binds the PA component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA technology in a murine cell expression system.
Raxibacumab is supplied as a sterile, liquid formulation in single-dose vials for intravenous infusion. Each vial contains 1,700 mg/34 mL (50 mg/mL) raxibacumab in citric acid (0.13 mg/mL), glycine (18 mg/mL), polysorbate 80 [0.2 mg/mL (w/v)], sodium citrate (2.8 mg/mL), and sucrose (10 mg/mL), with a pH of 6.5. Raxibacumab is a clear to opalescent, colorless to pale yellow, liquid.
Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs. Raxibacumab is also indicated for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
The effectiveness of raxibacumab is based solely on efficacy studies in animal models of inhalational anthrax. It is not ethical or feasible to conduct controlled clinical trials with intentional exposure of humans to anthrax. [See Clinical Studies]
Safety and pharmacokinetics (PK) of raxibacumab have been studied in adult healthy volunteers. There have been no trials of safety or PK of raxibacumab in the pediatric population. An extrapolation approach was used to derive dosing regimens that are predicted to provide pediatric patients with exposure comparable to the observed exposure in adults. [See Use In Specific Populations]
Raxibacumab binds to the protective antigen (PA) of B. anthracis; it does not have direct antibacterial activity. Raxibacumab does not cross the blood-brain barrier and does not prevent or treat meningitis. Raxibacumab should be used in combination with appropriate antibacterial drugs.
Administer raxibacumab as a single dose of 40 mg/kg intravenously over 2 hours and 15 minutes after dilution in 0.9% Sodium Chloride Injection, USP (normal saline) to a final volume of 250 mL. Administer 25 to 50 mg diphenhydramine within 1 hour prior to raxibacumab infusion to reduce the risk of occurrence and/or the severity of an infusion reaction. Diphenhydramine route of administration (oral or intravenous) should be based on the temporal proximity to the start of raxibacumab infusion. [See WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS]
The recommended dose for pediatric patients is based on weight as shown in Table 1.
Table 1: Recommended Pediatric Dose
| Pediatric Body Weight | Pediatric Dose |
| Greater than 40 kg | 40 mg/kg |
| Greater than 10 kg to 40 kg | 60 mg/kg |
| 10 kg or less | 80 mg/kg |
Premedicate with diphenhydramine within 1 hour prior to raxibacumab infusion to reduce the risk of occurrence and/or the severity of an infusion reaction. Diphenhydramine route of administration (oral or intravenous) should be based on the temporal proximity to the start of raxibacumab infusion. Infuse raxibacumab over 2 hours and 15 minutes. No pediatric patients were studied during the development of raxibacumab. The dosing recommendations in Table 1 are derived from simulations designed to match the observed adult exposure to raxibacumab at a 40 mg/kg dose. [See Use In Specific Populations]
The recommended dose of raxibacumab is weight-based, given as an intravenous infusion after dilution in a compatible solution to a final volume of 250 mL (in adults) or to a volume indicated based on the child’s weight (Table 2). Dilute raxibacumab using one of the following compatible solutions:
Keep vials in their cartons prior to preparation of an infusion solution to protect raxibacumab from light. Raxibacumab vials contain no preservative.
Table 2: Raxibacumab Dose, Diluents, Infusion Volumes and Rates by Body Weight
| Body Weight | Preparation | Administration | |||
| Dose | Total Infusion Volumea | Type of Diluent | Infusion Rate | Infusion Rate | |
| First 20 Minutes | Remaining Infusion | ||||
| Adults | |||||
| 40 mg/kg | 250 mL | 0.9% Sodium Chloride Injection | 15 mL/hour | 125 mL/hour | |
| Pediatric Patients (Younger than 18 Years) | |||||
| Less than 1 kg | 80 mg/kg | 7 mL | 0.45% Sodium Chloride | 0.5 mL/hour | 3.5 mL/hour |
| 1 kg to less than 2 kg | 15 mL | Injection | 1 mL/hour | 7 mL/hour | |
| 2 kg to less than 3 kg | 20 mL | or 0.9% Sodium Chloride Injection | 1.2 mL/hour | 10 mL/hour | |
| 3 kg to less than 5 kg | 25 mL | 1.5 mL/hour | 12 mL/hour | ||
| 5 kg to 10 kg | 40 mL | 3 mL/hour | 20 mL/hour | ||
| Greater than10 kg to less than 15 kg | 60 mg/kg | 50 mL | 0.9% Sodium Chloride Injection | 6 mL/hour | 25 mL/hour |
| 15 kg to less than 30 kg | 100 mL | 6 mL/hour | 50 mL/hour | ||
| 30 kg to 40 kg | 125 mL | 15 mL/hour | 62.5 mL/hour | ||
| Greater than 40 kg | 40 mg/kg | 150 mL | 15 mL/hour | 75 mL/hour | |
| a For patients requiring maximal fluid restriction, dilution factors can be adjusted at the discretion of the physician to a maximal concentration of 32 mg/mL. | |||||
Follow the steps below to prepare the raxibacumab intravenous infusion solution.
Based on the total infusion volume selected in Table 2, prepare either a syringe or infusion bag as appropriate following the steps below.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard the solution if particulate matter is present or color is abnormal. [See DESCRIPTION]
Administer the infusion solution as described in Table 2. The rate of infusion may be slowed or interrupted if the patient develops any signs of adverse reactions, including infusion-associated symptoms.
Injection: 1,700 mg/34 mL (50 mg/mL) solution in a single-use vial.
Raxibacumab is a sterile, preservative-free, clear to opalescent, colorless to pale yellow solution supplied in single-use vials containing 1,700 mg/34 mL (50 mg/mL) raxibacumab and is available in the following packaging configuration:
Contains one single-use vial of raxibacumab 1,700 mg/34 mL (NDC 71655-103-01).
Raxibacumab must be refrigerated at 2°C to 8°C (36°F to 46°F). DO NOT FREEZE. Protect the vial from exposure to light, prior to use. Brief exposure to light, as with normal use, is acceptable. Store vial in original carton until time of use.
Manufactured by: Emergent Manufacturing Operations Baltimore LLC, Baltimore, MD 21224, U.S. License No. 2083, Emergent BioSolutions Inc. Revised: Mar 2018
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of raxibacumab has been studied only in healthy volunteers. It has not been studied in patients with inhalational anthrax.
The safety of raxibacumab has been evaluated in 326 healthy subjects treated with a dose of 40 mg/kg in 3 clinical trials: a drug interaction trial with ciprofloxacin (Study 1), a repeat-dose trial of 20 subjects with the second raxibacumab dose administered ≥4 months after the first dose (Study 2), and a placebo-controlled trial evaluating single doses with a subset of subjects receiving 2 raxibacumab doses 14 days apart (Study 3). Raxibacumab was administered to 86 healthy subjects in Study 1. In Study 3, 240 healthy subjects received raxibacumab (217 received 1 dose and 23 received 2 doses) and 80 subjects received placebo.
The overall safety of raxibacumab was evaluated as an integrated summary of these 3 clinical trials. Of 326 raxibacumab subjects, 283 received single doses, 23 received 2 doses 14 days apart, and 20 received 2 doses more than 4 months apart. The subjects were aged 18 to 88 years, 53% female, 74% white, 17% black/African-American, 6% Asian, and 15% Hispanic.
Four subjects (1.2%) had their infusion of raxibacumab discontinued for adverse reactions: 2 subjects (neither of whom received diphenhydramine premedication) due to urticaria (mild), and 1 subject each discontinued for clonus (mild) and dyspnea (moderate).
The most frequently reported adverse reactions were rash, pain in extremity, pruritus, and somnolence.
Table 3: Adverse Reactions Reported in ≥1.5% of Healthy Adult Subjects Exposed to Raxibacumab 40 mg/kg Intravenously
| Preferred Term | Placebo n = 80 (%) | Single-Dose Raxibacumab n = 283 (%) | Double-Dose Raxibacumab ≥4 Months Apart n = 20(%) | Double-Dose Raxibacumab 2 Weeks Apart n = 23 (%) | Total Raxibacumab Subjects N = 326 (%) |
| Rash/Rash erythematous/Rash papular | 1 (13) | 9 (3.2) | 0 | 0 | 9 (2.8) |
| Pain in extremity | 1 (13) | 7(2.5) | 0 | 0 | 7(2.1) |
| Pruritus | 0 | 7(2.5) | 0 | 0 | 7(2.1) |
| Somnolence | 0 | 4(1.4) | 0 | 1 (4.3) | 5 (1.5) |
For all subjects exposed to raxibacumab in clinical trials, the rate of rash was 2.8% (9/326) compared with 1.3% (1/80) of placebo subjects. Mild to moderate infusionrelated rashes were reported in 22.2% (6/27) of subjects who did not receive diphenhydramine premedication compared with 3.3% (2/61) of subjects who were premedicated with diphenhydramine in the ciprofloxacin/raxibacumab combination trial (Study 1). In the placebo-controlled raxibacumab study where all subjects received diphenhydramine (Study 3), the rate of rash was 2.5% in both placebo- and raxibacumab-treated subjects.
Clinically significant adverse reactions that were reported in <1.5% of subjects exposed to raxibacumab and at rates higher than in placebo subjects are listed below:
The development of anti-raxibacumab antibodies was evaluated in all subjects receiving single and double doses of raxibacumab in Studies 1, 2, and 3. Immunogenic responses against raxibacumab were not detected in any raxibacumab-treated human subjects following single or repeat doses of raxibacumab.
The incidence of antibody formation is highly dependent on the sensitivity and specificity of the immunogenicity assay. Additionally, the observed incidence of any antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to raxibacumab with the incidence of antibodies to other products may be misleading.
Co-administration of 40 mg/kg raxibacumab intravenously with intravenous or oral ciprofloxacin in human subjects did not alter the PK of either ciprofloxacin or raxibacumab [see CLINICAL PHARMACOLOGY].
Included as part of the PRECAUTIONS section.
Infusion-related reactions were reported during administration of raxibacumab in clinical trials including reports of rash, urticaria, and pruritus. If these reactions occur, slow or interrupt raxibacumab infusion and administer appropriate treatment based on severity of the reaction.
Premedicate with diphenhydramine within 1 hour prior to administering raxibacumab to reduce the risk of occurrence and/or the severity of an infusion reaction [see DOSAGE AND ADMINISTRATION, ADVERSE REACTIONS].
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Inform patients that the efficacy of raxibacumab is based solely on efficacy studies demonstrating a survival benefit in animals and that the effectiveness of raxibacumab has not been tested in humans with anthrax. The safety of raxibacumab has been tested in healthy adults, but no safety data are available in children or pregnant women. Limited data are available in geriatric patients. [See Use In Specific Populations]
Infusion-related reactions were reported during administration of raxibacumab in clinical trials, including reports of rash, urticaria, and pruritus. Prophylactic administration of diphenhydramine is recommended within 1 hour prior to administering raxibacumab. Diphenhydramine route of administration (oral or intravenous) should be based on the temporal proximity to the start of raxibacumab infusion.
Carcinogenicity, genotoxicity, and fertility studies have not been conducted with raxibacumab.
There are no data on the use of raxibacumab in pregnant women to inform on drug-associated risk. In pregnant rabbits, intravenous administration of raxibacumab was not associated with teratogenicity or other adverse developmental outcomes at 3 times the human maximum plasma concentrations at the maximum recommended adult dose (see Data).
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background rate of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.
Disease-Associated Maternal And/Or Embryo/Fetal Risk
Limited data in the form of case reports of anthrax infection in pregnant women indicate that maternal infection is associated with a high risk of maternal, fetal, and neonatal deaths, particularly in the absence of treatment.
Animal Data
A study was conducted in pregnant, healthy New Zealand White rabbits administered intravenous raxibacumab at dose levels of 40 or 120 mg/kg on Gestation Days 7 and 14. No teratogenicity or other adverse developmental outcomes were observed in pregnant rabbits at 3 times the human maximum plasma concentrations at the maximum recommended adult dose of 40 mg/kg. Maternal toxicity was observed at both doses (reduced body weight gain late in gestation, but no difference in mean total weight gain).
There is no information available on the presence of raxibacumab in human milk, the effects on the breastfed child, or the effects on milk production. Maternal IgG is known to be present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for raxibacumab and any potential adverse effects on the breastfed child from raxibacumab or from the underlying maternal condition.
As in adults, the effectiveness of raxibacumab in pediatric patients is based solely on efficacy studies in animal models of inhalational anthrax. As exposure of healthy children to raxibacumab is not ethical, an extrapolation approach was used to derive dosing regimens that are predicted to provide pediatric patients with exposure comparable to the observed exposure in adults receiving 40 mg/kg. The dose for pediatric patients is based on weight. [See DOSAGE AND ADMINISTRATION]
Safety or PK of raxibacumab have not been studied in the pediatric population.
Clinical trials of raxibacumab did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects. Of the total number of subjects in clinical trials of raxibacumab, 6.4% (21/326) were 65 years and older, while 1.5% (5/326) were 75 years and older. However, no alteration of dosing is needed for patients aged 65 years and older [see CLINICAL PHARMACOLOGY].
There is no clinical experience with overdosage of raxibacumab. In case of overdosage, monitor patients for any signs or symptoms of adverse effects.
None.
Raxibacumab is a monoclonal antibody that binds the PA of B. anthracis [see CLINICAL PHARMACOLOGY].
The PK of raxibacumab is linear over the dose range of 1 to 40 mg/kg following single intravenous dosing in humans; raxibacumab was not tested at doses higher than 40 mg/kg in humans. Following single intravenous administration of raxibacumab 40 mg/kg in healthy, male and female human subjects, the mean Cmax and AUCinf were 1,020.3 ± 140.6 mcg/mL and 15,845.8 ± 4,333.5 mcg•day/mL, respectively. Mean raxibacumab steady-state volume of distribution was greater than plasma volume, suggesting some tissue distribution. Clearance values were much smaller than the glomerular filtration rate indicating that there is virtually no renal clearance of raxibacumab.
Because the effectiveness of raxibacumab cannot be tested in humans, a comparison of raxibacumab exposures achieved in healthy human subjects to those observed in animal models of inhalational anthrax in therapeutic efficacy studies is necessary to support the dosage regimen of 40 mg/kg intravenously as a single dose for the treatment of inhalational anthrax in humans. Humans achieve similar or greater systemic exposure (Cmax and AUCinf) to raxibacumab following a single 40 mg/kg intravenous dose compared with New Zealand White rabbits and cynomolgus macaques receiving the same dosage regimen.
Raxibacumab PK was evaluated via a population PK analysis using serum samples from 322 healthy subjects who received a single 40 mg/kg intravenous dose across 3 clinical trials. Based on this analysis, gender (female versus male), race (non-white versus white), or age (elderly versus young) had no meaningful effects on the PK parameters for raxibacumab.
Raxibacumab PK has not been evaluated in children [see DOSAGE AND ADMINISTRATION, Use In Specific Populations].
Although raxibacumab is intended for single-dose administration, the PK of raxibacumab following a second administration of 40 mg/kg given intravenously 14 days after the first 40-mg/kg intravenous dose was assessed in 23 healthy subjects (Study 3). The mean raxibacumab concentration at 28 days after the second dose was approximately twice the mean raxibacumab concentration at 14 days following the first dose. In the human trial assessing the immunogenicity of raxibacumab (Study 2), 20 healthy subjects who had initially received a single dose of raxibacumab 40 mg/kg intravenously received a second 40 mg/kg intravenous dose at ≥4 months following their first dose. No statistically significant differences in mean estimates of AUCinf, CL, or half-life of raxibacumab between the 2 doses administered ≥4 months apart were observed. The mean Cmax following the second dose was 15% lower than the Cmax following the first dose.
In an open-label trial evaluating the effect of raxibacumab on ciprofloxacin PK in healthy adult male and female subjects (Study 1), the administration of 40 mg/kg raxibacumab intravenously following ciprofloxacin intravenous infusion or ciprofloxacin oral tablet ingestion did not alter the PK of ciprofloxacin administered orally and/or intravenously. Likewise, ciprofloxacin did not alter the PK of raxibacumab. [See DRUG INTERACTIONS]
Raxibacumab is a monoclonal antibody that binds free PA with an affinity equilibrium dissociation constant (Kd) of 2.78 ± 0.9 nM. Raxibacumab inhibits the binding of PA to its cellular receptors, preventing the intracellular entry of the anthrax lethal factor and edema factor, the enzymatic toxin components responsible for the pathogenic effects of anthrax toxin.
Raxibacumab binds in vitro to PA from the Ames, Vollum, and Sterne strains of B. anthracis. Raxibacumab binds to an epitope on PA that is conserved across reported strains of B. anthracis.
In vivo studies in rats suggest that raxibacumab neutralizes the toxicity due to lethal toxin, as animals slowly infused with lethal toxin (a combination of PA + lethal factor) survived 7 days following administration. The median time to death in control rats was 16 hours. Similar observations were noted in animal efficacy studies in rabbits and monkeys challenged with B. anthracis spores by the inhalational route. PA was detected in animals following exposure to B. anthracis spores. PA levels rose and then fell to undetectable levels in animals that responded to treatment and survived, whereas levels continued to rise in animals that failed treatment and died or were euthanized because of poor clinical condition. [See Clinical Studies]
Because it is not feasible or ethical to conduct controlled clinical trials in humans with inhalational anthrax, the effectiveness of raxibacumab for therapeutic treatment of inhalational anthrax is based on efficacy studies in rabbits and monkeys. Raxibacumab effectiveness has not been studied in humans. Because the animal efficacy studies are conducted under widely varying conditions, the survival rates observed in the animal studies cannot be directly compared between studies and may not reflect the rates observed in clinical practice.
The efficacy of raxibacumab for treatment of inhalational anthrax was studied in a monkey model (Study 2) and a rabbit model (Studies 3 and 4) of inhalational anthrax disease. These 3 studies tested raxibacumab efficacy compared with placebo. Another study in a rabbit model (Study 1) evaluated the efficacy of raxibacumab in combination with an antibacterial drug relative to the antibacterial drug alone. Studies were randomized and blinded.
The animals were challenged with aerosolized B. anthracis spores (Ames strain) at 200 x LD50 to achieve 100% mortality if untreated. In rabbit Study 1, treatment was delayed until 84 hours after spore challenge. In monkey Study 2, study treatment commenced at the time of a positive serum electrochemiluminescence (ECL) assay for B. anthracis PA. The mean time between spore challenge and initiation of study treatment was 42 hours. In rabbit Studies 3 and 4, sustained elevation of body temperature above baseline for 2 hours or a positive result on serum ECL assay for PA served as the trigger for initiation of study treatment. The mean time between spore challenge and initiation of study treatment was 28 hours post-exposure. Efficacy in all therapeutic studies in animals was determined based on survival at the end of the study. Most study animals (88% to 100%) were bacteremic and had a positive ECL assay for PA prior to treatment in all 4 studies.
The efficacy of raxibacumab administered with levofloxacin as treatment of animals with systemic anthrax disease (84 hours after spore challenge) was evaluated in New Zealand White rabbits (Study 1). The dose of levofloxacin was chosen to yield a comparable exposure to that achieved by the recommended doses in humans. Levofloxacin and raxibacumab PK in this study were unaffected by product co-administration. Forty-two percent of challenged animals survived to treatment. Treatment with antibacterial drug plus raxibacumab resulted in 82% survival compared with 65% survival in rabbits treated with antibacterial drug alone, P = 0.0874 (Table 4).
Table 4: Survival Rates in NZW Rabbits in Combination Therapy Study, All Treated Animals
| NZW Rabbits (35 days)a Study 1 | |||
| Number (%) Survivors | P Valueb | 95% CIc Levofloxacin versus Levofloxacin + Raxibacumab | |
| Levofloxacin alone | 24/37 (65%) | - | - |
| Levofloxacin + Raxibacumab 40 mg/kg intravenous single dose | 32/39 (82%) | 0.0874 | (-2.4, 36.7) |
| aSurvival assessed 28 days after last dose of levofloxacin. bP value based on a two-sided likelihood ratio chi-square test. c95% confidence interval based on normal approximation. | |||
Monkey Study 2 and rabbit Studies 3 and 4 evaluated treatment with raxibacumab alone at an earlier time point after exposure than rabbit Study 1. Treatment with raxibacumab alone resulted in a statistically significant dose-dependent improvement in survival relative to placebo when administered at the time of initial manifestations of anthrax disease in the rabbit and monkey infection models (Table 5). Raxibacumab at 40-mg/kg intravenous single dose was superior to placebo in the rabbit and monkey studies in the all treated and the bacteremic animal analysis populations. All surviving animals developed toxin-neutralizing antibodies.
Table 5: Survival Rates in Animals Treated with Raxibacumab, All Treated Animals
| Study Drug | Cynomolgus Macaques at 28 Daysa Study 2 | NZW Rabbits at 14 Daysb Study 3 | NZW Rabbits at 28 Daysa Study 4 | ||||||
| Number (%) Survivors | P Valuec | 95% CId | Number (%) Survivors | P Valuec | 95% CId | Number (%) Survivors | P Valuec | 95% CId | |
| Placebo | 0/12 | 0/17 | 0/24 | ||||||
| 20 mg/kg raxibacumab | 7/14 (50%) | 0.0064 | (19.3, 73.7) | 5/18 (28%) | 0.0455 | (6.6, 52.5) | - | - | - |
| 40 mg/kg raxibacumab | 9/14 (64%) | 0.0007 | (31.6, 84.7) | 8/18 (44%) | 0.0029 | (21.3, 66.7) | 11/24 (46%) | 0.0002 | (27.0, 66.1) |
| aSurvival measured at 28 days after spore challenge. bSurvival measured at 14 days after spore challenge. cP value based on two-sided Fisher's exact test for comparisons between raxibacumab and placebo. d95% CIs are exact confidence intervals for the difference between raxibacumab and placebo. | |||||||||
In other animal studies evaluating antibacterial drug alone and raxibacumab-antibacterial drug combination, the efficacy of an antibacterial drug alone (levofloxacin in rabbits and ciprofloxacin in monkeys) was very high (95% to 100%) when given at the initial manifestations of inhalational anthrax disease. The timing of treatment was similar to that reported for Studies 2, 3, and 4 above.
In another study, rabbits were exposed to 100 times LD B. anthracis spores and administered raxibacumab at a single dose of 40 mg/kg at the time of exposure, 12 hours, 24 hours, or 36 hours after exposure. Survival was 12/12 (100%) in animals treated at time of exposure or 12 hours, but decreased to 6/12 (50%) and 5/12 (42%) at 24 hours and 36 hours, respectively.
Healthy cynomolgus macaques administered 3 intravenous doses or 3 subcutaneous doses of 40 mg/kg raxibacumab once every 12 days, or a single intramuscular dose (40 mg/kg) of raxibacumab, showed no adverse effects, including no effects up to 120 days post-dosing.
Studies with raxibacumab in rabbit, cynomolgus macaque, and human donor tissues showed no cross reactivity with brain.
Anthrax-infected rabbits and monkeys administered an intravenous injection of raxibacumab (40 mg/kg) at time of PA toxemia reproducibly showed greater severity of central nervous system (CNS) lesions (bacteria, inflammation, hemorrhage, and necrosis) in non-surviving animals compared with dead placebo-control animals, with no difference in mean time to death from spore challenge. The raxibacumab monoclonal antibody appears unable to penetrate the CNS until compromise of the bloodbrain barrier (BBB) during the later stages of anthrax infection. The most severe brain lesions in rabbits were associated with bacteria and raxibacumab tissue binding in a similar pattern as endogenous IgG antibody that leaked across the compromised BBB. No dose/exposure-response relationship for brain histopathology was identified. Surviving rabbits and monkeys at the end of the 28-day studies showed no microscopic evidence of CNS lesions. CNS toxicity was not observed in healthy monkeys administered raxibacumab (40 mg/kg) or in GLP combination treatment studies with antibacterials in rabbits (levofloxacin) or in monkeys (ciprofloxacin) at any time.
RAXIBACUMAB
(rack-see-BACK-u-mab)
Injection, for intravenous use
What is RAXIBACUMAB?
Before you receive RAXIBACUMAB, tell your healthcare provider about all of your medical conditions, including if you are:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive RAXIBACUMAB?
What are the possible side effects of RAXIBACUMAB?
RAXIBACUMAB may cause serious side effects, including:
The most common side effects of RAXIBACUMAB include rash, pain in your arms or legs, itchiness, and sleepiness.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of RAXIBACUMAB. For more information, ask your healthcare provider.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov.
General information about the safe and effective use of RAXIBACUMAB.
What are the ingredients in RAXIBACUMAB?
Active ingredient: RAXIBACUMAB
Inactive ingredients: citric acid, glycine, polysorbate 80, sodium citrate, sucrose, Water for Injection
This Patient Information has been approved by the U.S. Food and Drug Administration.
